Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2007 May 15;109(10):4164-7.
doi: 10.1182/blood-2006-09-045351. Epub 2007 Jan 30.

Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511

Meir Wetzler  1 , Ben L Sanford, Joanne Kurtzberg, Divino DeOliveira, Stanley R Frankel, Bayard L Powell, Jonathan E Kolitz, Clara D Bloomfield, Richard A Larson
Affiliations
Clinical Trial

Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511

Meir Wetzler et al. Blood. .

Abstract

CALGB 9511 used pegaspargase (PEG-ASP) in lieu of the native enzyme. The aim was to compare differences in overall survival (OS) and disease-free survival (DFS) between patients who did and did not achieve asparagine depletion, defined by enzyme levels greater than 0.03 U/mL plasma for 14 consecutive days after at least 1 of 4 planned PEG-ASP administrations. Samples were available from 85 eligible patients. On univariate analyses, the 22 patients who did not achieve asparagine depletion had inferior OS (P = .002; hazard ratio [HR] = 2.37; 95% CI = 1.38-4.09) and DFS (P = .012; HR = 2.21; 95% CI = 1.19-4.13). After adjusting for age, performance status, leukocyte count, and karyotype in a proportional hazards model, both the OS and DFS HRs decreased to 1.8 (P = .056; 95% CI = 1.0-3.2 and P = .084; 95% CI = 0.9-3.6, respectively). We conclude that effective asparagine depletion with PEG-ASP is feasible as part of an intensive multiagent therapeutic regimen in adult acute lymphoblastic leukemia and appears associated with improved outcomes.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Survival of 63 patients with ALL who achieved asparagine depletion, compared with 22 patients who did not.
See this image and copyright information in PMC

References

    1. Broome JD. Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects. Nature. 1961;191:1114–1115. - PMC - PubMed
    1. Keating MJ, Holmes R, Lerner S, Ho DH. L-asparaginase and PEG asparaginase— past, present, and future. Leuk Lymphoma. 1993;10(suppl):153–157. - PubMed
    1. Asselin BL, Whitin JC, Coppola DJ, Rupp IP, Sallan SE, Cohen HJ. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol. 1993;11:1780–1786. - PubMed
    1. Asselin BL, Ryan D, Frantz CN, et al. In vitro and in vivo killing of acute lymphoblastic leukemia cells by L-asparaginase. Cancer Res. 1989;49:4363–4368. - PubMed
    1. Ettinger LJ, Kurtzberg J, Voute PA, Jurgens H, Halpern SL. An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia. Cancer. 1995;75:1176–1181. - PubMed

Publication types